BMO
MDXG icon

Beck Mack & Oliver’s MiMedx Group MDXG Stock Holding History

Beck Mack & Oliver’s Portfolio MDXG Stock Details MDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-14,685
Closed -$97.1K – 173
2023
Q2 		$97.1K Sell
14,685
-590,993
-98% -$3.01M ﹤0.01% 169
2023
Q1 		$2.07M Sell
605,678
-394,857
-39% -$1.53M 0.06% 83
2022
Q4 		$2.78M Sell
1,000,535
-24,600
-2% -$73.5K 0.08% 80
2022
Q3 		$2.94M Buy
1,025,135
+107,550
+12% +$382K 0.1% 79
2022
Q2 		$3.18M Buy
917,585
+163,765
+22% +$641K 0.1% 76
2022
Q1 		$3.55M Buy
753,820
+545,507
+262% +$2.67M 0.09% 77
2021
Q4 		$1.26M Buy
208,313
+145,435
+231% +$1.01M 0.03% 107
2021
Q3 		$381K Sell
62,878
-212,003
-77% -$2.39M 0.01% 160
2021
Q2 		$3.44M Buy
274,881
+24,776
+10% +$268K 0.09% 71
2021
Q1 		$2.58M Buy
250,105
+4,845
+2% +$46.8K 0.08% 75
2020
Q4 		$2.23M Buy
245,260
+111,320
+83% +$801K 0.07% 82
2020
Q3 		$851K Buy
+133,940
New +$851K 0.03% 112

Other funds holding MDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Beck Mack & Oliver's MDXG Position: Q3 2023 in Review

Beck Mack & Oliver sold out of MiMedx Group (MDXG) in Q3 2023, closing a stake of 14,685 shares — an estimated $97.1K sold.

Beck Mack & Oliver first reported a position in MDXG in Q3 2020 and held it in 12 quarters. The position peaked at $3.55M in Q1 2022. 185 funds tracked by Wall St. Rank hold MDXG as of Q3 2023.

  • Beck Mack & Oliver reported no remaining MiMedx Group position as of Q3 2023 after selling out during the quarter.
  • Beck Mack & Oliver sold 14,685 MiMedx Group shares in Q3 2023, an estimated $97.1K.
  • Beck Mack & Oliver first reported a position in MiMedx Group in Q3 2020 and held it in 12 quarters.
  • Beck Mack & Oliver's MiMedx Group position peaked at $3.55M in Q1 2022.
  • 185 funds tracked by Wall St. Rank held MiMedx Group as of Q3 2023.

Based on Beck Mack & Oliver's 13F filing for Q3 2023, filed 14 Nov 2023.